Overview

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status:
Not yet recruiting

Trial end date:
2028-09-29

Target enrollment:

Participant gender:

Summary

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Acalabrutinib
Obinutuzumab
Venetoclax